adssx
#924
2 Likes
Keeping glucose low strikes me as a good strategy. Avoid glucose spikes.
3 Likes
adssx
#926
SGLT2i are also mild brain-penetrant mTOR inhibitors (indirectly?):
2 Likes
adssx
#927
Combination therapies: a change in approach for Parkinson’s research
Therefore, we aim to encourage researchers to think about, and test, drug combinations earlier in the drug discovery process; Cure Parkinson’s are championing the testing of combination therapies with the hope of increasing the odds of identifying disease-modifying therapies with urgency.
To kick start this change, Cure Parkinson’s will be opening a £2 million funding call in October 2025 to encourage the testing of combination therapies for Parkinson’s.
@John_Hemming: which combinations would you like to see tested? Citrate + melatonin + K2 I guess?
1 Like
That would be a good start, but these things have important aspects relating to dosing and timing of dose. I don’t think CP would want to try 1g of melatonin at night, for example, or even 100mg.
It is one really which requires individual experimentation with potentially quite substantial doses
Well, that really opens up possibilities. In particular, combining drugs where one or both individually may have failed, because the combination is a whole new effect - we’ve seen this over and over again, like the mice lifespan studies I discussed recently - metformin alone failed but in combo with rapa worked, or simvastatin and ramipril both failed individually, but gave a good 9% extension combined.
There were several very promising drugs which we had high hopes for PD for mechanistic reasons, but which sadly and disappointingly failed trials. Combining them might give them a new lease on life. I think that’s a very exciting possibility. We might be giving up on some drugs too soon!
